Patents by Inventor Duc-Hanh Thi Nguyen

Duc-Hanh Thi Nguyen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Optimized antibodies that target HM1.24
    Patent number: 9040042
    Abstract: The present disclosure describes antibodies that target HM1.24. In various aspects, the antibodies have specific CDR, variable, or full length sequences, have modifications with the parent antibody, or include at least one modification relative to a parent antibody that alters affinity to an Fc?R or alters effector function as compared to the parent antibody. Nucleic acids encoding the antibodies and methods of using the antibodies are also disclosed.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: May 26, 2015
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Umesh S. Muchhal, Duc-Hanh Thi Nguyen, John O. Richards
  • Optimized antibodies that target HM1.24
    Patent number: 8394374
    Abstract: The present disclosure describes antibodies that target HM1.24. In various aspects, the antibodies have specific CDR, variable, or full length sequences, have modifications with the parent antibody, or include at least one one modification relative to a parent antibody that alters affinity to an Fc?R or alters effector function as compared to the parent antibody. Nucleic acids encoding the antibodies and methods of using the antibodies are also disclosed.
    Type: Grant
    Filed: September 18, 2007
    Date of Patent: March 12, 2013
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Umesh S. Muchhal, Duc-Hanh Thi Nguyen, John O. Richards
  • Method of treatment using adiponectin variants
    Patent number: 7749956
    Abstract: A method of treating a mammal with an adiponectin mediated disorder comprising administering a therapeutically effective amount of an adiponectin variant with at least a 3-fold increased solubility relative to residues 110-244 of human adiponectin.
    Type: Grant
    Filed: May 30, 2006
    Date of Patent: July 6, 2010
    Assignee: Xencor, Inc.
    Inventors: Jonathan Zalevsky, Duc-Hanh Thi Nguyen, Gregory L. Moore, Sergei A. Ezhevsky, John R. Desjarlais, Arthur J. Chirino, Darian Cash, Matthew J. Bernett
  • Adiponectin variants
    Patent number: 7709607
    Abstract: An adiponectin variant with one or more amino acid modifications relative to a corresponding parent adiponectin, wherein the solubility of the variant is improved by at least 3-fold relative to residues 110-244 of human adiponectin.
    Type: Grant
    Filed: May 30, 2006
    Date of Patent: May 4, 2010
    Assignee: Xencor, Inc.
    Inventors: Jonathan Zalevsky, Duc-Hanh Thi Nguyen, Gregory L. Moore, Sergei A. Ezhevsky, John R. Desjarlais, Arthur J. Chirino, Darian Cash, Matthew J. Bernett
  • Optimized Antibodies that Target HM1.24
    Publication number: 20100104557
    Abstract: The present disclosure describes antibodies that target HM1.24. In various aspects, the antibodies have specific CDR, variable, or full length sequences, have modifications with the parent antibody, or include at least one one modification relative to a parent antibody that alters affinity to an Fc?R or alters effector function as compared to the parent antibody. Nucleic acids encoding the antibodies and methods of using the antibodies are also disclosed.
    Type: Application
    Filed: September 18, 2007
    Publication date: April 29, 2010
    Applicant: Xencor, Inc.
    Inventors: Matthew J. Bernett, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Umesh S. Muchhal, Duc-Hanh Thi Nguyen, John O. Richards
  • Pharmaceutical compositions of adiponectin variants and methods of storage
    Patent number: 7678886
    Abstract: A composition comprising an adiponectin variant at a concentration of at least 2.0 mg/mL, and a pharmaceutically acceptable carrier, wherein less than 20% of said adiponectin variant would aggregate after storage at 4° C. for one week in 10 mM PO4, 150 mM NaCl buffer.
    Type: Grant
    Filed: May 30, 2006
    Date of Patent: March 16, 2010
    Assignee: Xencor, Inc.
    Inventors: Jonathan Zalevsky, Duc-Hanh Thi Nguyen, Gregory L. Moore, Sergei A. Ezhevsky, John R. Desjarlais, Arthur J. Chirino, Darian Cash, Matthew J. Bernett
  • Globular adiponectin variants
    Patent number: 7592423
    Abstract: An adiponectin variant with one or more amino acid modifications relative to a corresponding parent adiponectin, wherein the adiponectin variant is not glycosylated, the adiponectin variant does not have residues 1-100 relative to human adiponectin, and wherein the solubility of the variant is improved by at least 3-fold relative to residues 110-244 of human adiponectin.
    Type: Grant
    Filed: May 30, 2006
    Date of Patent: September 22, 2009
    Assignee: Xencor, Inc.
    Inventors: Jonathan Zalevsky, Duc-Hanh Thi Nguyen, Gregory L. Moore, Sergei A. Ezhevsky, John R. Desjarlais, Arthur J. Chirino, Darian Cash, Matthew J. Bernett
  • OPTIMIZED ANTIBODIES THAT TARGET HM1.24
    Publication number: 20080219974
    Abstract: The present disclosure describes antibodies that target HM1.24. In various aspects, the antibodies have specific CDR, variable, or full length sequences, have modifications with the parent antibody, or include at least one modification relative to a parent antibody that alters affinity to an Fc?R or alters effector function as compared to the parent antibody. Nucleic acids encoding the antibodies and methods of using the antibodies are also disclosed.
    Type: Application
    Filed: September 18, 2007
    Publication date: September 11, 2008
    Inventors: Matthew J. Bernett, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Umesh S. Muchhal, Duc-Hanh Thi Nguyen, John O. Richards
  • Pharmaceutical Compositions of Adiponectin Variants and Methods of Storage
    Publication number: 20060276395
    Abstract: 1. A composition comprising an adiponectin variant at a concentration of at least 2.0 mg/mL, and a pharmaceutically acceptable carrier, wherein less than 20% of said adiponectin variant would aggregate after storage at 4° C. for one week in 10 mM PO4, 150 mM NaCl buffer.
    Type: Application
    Filed: May 30, 2006
    Publication date: December 7, 2006
    Inventors: Jonathan Zalevsky, Duc-Hanh Thi Nguyen, Gregory Moore, Sergei Ezhevsky, John Desjarlais, Arthur Chirino, Darian Cash, Matthew Bernett